Share via Email

* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is
* Email Subject: (personalize your subject)

Email Content: Poultry Industry News, Comments and more by Simon M. Shane

Elanco Animal Health Reports on Q4 and FY2018


In a February 6th release, Elanco Animal Health Inc. (ELAN) reported on the 4th Quarter and Fiscal 2018 ending December 31st.

For the quarter, the company earned $16.4 million on revenue of $799.3 million. The net profit value included an $18.6 million tax benefit offsetting an operating loss of $2.2 million. Expenses included a $55 million charge associated with restructuring and impairment of assets. For the corresponding quarter in FY 2017, ELAN posted a loss of $161.5 million on sales of $754.3 million. Expenses included $185 million in restructuring and impairment of assets.

For fiscal 2018, the company earned $86.5 million on sales of $3.07 billion generating an EPS of $0.28. For fiscal 2017, the company attained a loss of $310.7 million on sales of $2.89 billion with a corresponding EPS of ($1.06).

For 2018, companion animal products represented 35 percent of revenue compared to 32 percent in fiscal 2017. Sales of food animal products decreased from 63 percent in FY2017 to 61 percent for the past year.

The company provided guidance for fiscal 2019 including a range in sales of $3.1 billion to $3.6 billion and EPS of $0.36 to $0.38.

ELAN listed total assets of $8.94 billion of which 63 percent comprise intangibles and trademarks.

Elanco has a market capitalization of $10.6 billion and a forward P/E of 26.6.

The 52-week share price has ranged from $28.00 to $37.60 and closed on February 6th at $29.01.

The profit margin for ELAN at -3.0 percent can be compared to Zoetis at 20.4 percent. Respective operating margins of the two companies are ELAN 9.8 percent and Zoetis 34.3 percent.

Copyright 2019 Simon M. Shane